Table 2.

Summary of anti-VEGF treatment outcomes in fibrovascular PEDs

Study	Study type	No. of eyes	Drug	Follow-up (year)	Mean VA change	Mean no. of injections	Mean change in PED height	RPE tear rate
Au et al.	Retrospective	88	Bevacizumab, ranibizumab, aflibercept	1	−5 letters	10	−105.9 μm	Not reported
Balaskas et al.	Retrospective	110	Ranibizumab, aflibercept	1	5 letters	6.6	−71.5 μm	6.4%
Cho et al.	Retrospective	202	Ranibizumab, aflibercept	1	5 letters	4.9	−223 μm	9.9%
Sarraf et al.	Post hoc analysis	598	Ranibizumab	2	7.9 letters	14 (PRN 0.5 mg group)	−178.6 μm	4.7%
Inoue et al.	Prospective	57	Ranibizumab	1	< 5 letters	6	Not reported	1.8%
Panos et al.	Prospective	62	Ranibizumab	1	5 letters	6.6	−157.5 μm	1.6%
Chen et al.	Prospective	36	Aflibercept	1	6.5 letters	10	−347 μm	13.9%

VEGF: vascular endothelial growth factor, PED: pigment epithelial detachment